Editorial: FibroTest to predict liver-related mortality in NAFLD. Should this change the diagnostic algorithm in NAFLD?

Bush AM; Torres DM

doi:10.1111/apt.15036

Editorial: FibroTest to predict liver-related mortality in NAFLD. Should this change the diagnostic algorithm in NAFLD?

MeSH — NLM indexing Algorithms Hepatitis C, Chronic Humans Liver Liver Diseases, Alcoholic Non-alcoholic Fatty Liver Disease Prognosis

Azioni del personale

Scarica PDF

I file sono per uso autorizzato solo nei canali dei partner BioPredictive.

Fibrotest Actitest Comment Independent Group United States

Autori (2)

Bush AM — Walter Reed National Military Medical Center, Bethesda, Maryland.
Torres DM — Walter Reed National Military Medical Center, Bethesda, Maryland.

Citazione

Bush AM, Torres DM. Editorial: FibroTest to predict liver-related mortality in NAFLD. Should this change the diagnostic algorithm in NAFLD?. Aliment Pharmacol Ther. 2018;48(11-12):1319-1320. doi:10.1111/apt.15036.

Identificatori

DOI: 10.1111/apt.15036
PMID: 30488622

Test

Malattie del fegato

Lesioni epatiche

Regione

Carrello

Il carrello è vuoto.

Sfoglia le pubblicazioni e usa Aggiungi al carrello su qualsiasi pagina di dettaglio per creare un archivio ZIP da inviare ai clienti.

Sfoglia le pubblicazioni

Editorial: FibroTest to predict liver-related mortality in NAFLD. Should this change the diagnostic algorithm in NAFLD?

Altro sullo stesso argomento

An Invisible Early Steatosis Phenotype Defined for a Large Population-Based Cohort.

Diagnostic performance of FibroTest-ActiTest, transient elastography, and the fibrosis-4 index in patients with autoimmune hepatitis using histological reference.

Metabolic dysfunction-associated steatotic liver disease (MASLD) biomarkers and progression of lower limb arterial calcification in patients with type 2 diabetes: a prospective cohort study.

Noninvasive Assessment of Liver Fibrosis.

Screening for Metabolic Dysfunction-Associated Steatotic Liver Disease-Related Advanced Fibrosis in Diabetology: A Prospective Multicenter Study.

Three Neglected STARD Criteria Reduce the Uncertainty of the Liver Fibrosis Biomarker FibroTest-T2D in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).